CRISPR Therapeutics AG (CRSP) Operating Income (2016 - 2025)
Historic Operating Income for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$154.8 million.
- CRISPR Therapeutics AG's Operating Income fell 13961.73% to -$154.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$664.6 million, marking a year-over-year decrease of 4243.91%. This contributed to the annual value of -$664.6 million for FY2025, which is 4243.88% down from last year.
- Per CRISPR Therapeutics AG's latest filing, its Operating Income stood at -$154.8 million for Q4 2025, which was down 13961.73% from -$132.1 million recorded in Q3 2025.
- CRISPR Therapeutics AG's Operating Income's 5-year high stood at $762.6 million during Q2 2021, with a 5-year trough of -$229.3 million in Q2 2025.
- For the 5-year period, CRISPR Therapeutics AG's Operating Income averaged around -$82.7 million, with its median value being -$132.2 million (2023).
- In the last 5 years, CRISPR Therapeutics AG's Operating Income soared by 104513.25% in 2021 and then plummeted by 19282.15% in 2024.
- CRISPR Therapeutics AG's Operating Income (Quarter) stood at -$145.7 million in 2021, then grew by 9.72% to -$131.5 million in 2022, then soared by 152.9% to $69.6 million in 2023, then tumbled by 192.82% to -$64.6 million in 2024, then tumbled by 139.62% to -$154.8 million in 2025.
- Its Operating Income was -$154.8 million in Q4 2025, compared to -$132.1 million in Q3 2025 and -$229.3 million in Q2 2025.